Ocular Therapeutix (OCUL) Research & Development (2013 - 2026)
Ocular Therapeutix (OCUL) posted Research & Development of $54.14 million for Q2 2026, up 6.0% from $51.08 million a year earlier but down 18.2% from the prior quarter.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Research & Development (2013 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Ocular Therapeutix was $223.51 million, up 30.0% year-over-year; for FY2025, it was $197.1 million, up 54.4% from FY2024.
- Annual Research & Development has increased for five consecutive years, with a five-year compound annual growth rate of 47.0% (FY2020 to FY2025).
- In prior years, Ocular Therapeutix's Research & Development was $127.64 million in FY2024 (+109.0%), $61.06 million in FY2023 (+14.2%), $53.46 million in FY2022 (+6.7%) and $50.08 million in FY2021 (+74.5%).
- Quarterly Research & Development has run from a low of $12.58 million in Q4 2021 to a high of $66.21 million in Q1 2026 over five years.
- On a year-over-year basis, Research & Development has increased in each of the last 16 quarters, with growth averaging 76.2% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was Q4 2024, with growth of 153.1%; the weakest was Q2 2022, with a decline of 5.5%.
- According to Business Quant data, Research & Development for the three prior quarters was $66.21 million (Q1 2026), $50.8 million (Q4 2025) and $52.36 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.54 Bn | 572.07 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 467.01 Bn | 440.17 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.16 Bn | 321.59 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 277.56 Bn | 233.43 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 258.23 Bn | 231.79 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 224.14 Bn | 179.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.30 Bn | 161.42 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.47 Bn | 110.41 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.31 Bn | 105.31 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 11.46 Mn | 54.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.14 Mn |
| Mar 31, 2026 | 66.21 Mn |
| Dec 31, 2025 | 50.80 Mn |
| Sep 30, 2025 | 52.36 Mn |
| Jun 30, 2025 | 51.08 Mn |
| Mar 31, 2025 | 42.86 Mn |
| Dec 31, 2024 | 40.99 Mn |
| Sep 30, 2024 | 37.05 Mn |
| Jun 30, 2024 | 28.86 Mn |
| Mar 31, 2024 | 20.74 Mn |
| Dec 31, 2023 | 16.20 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 15.09 Mn |
| Mar 31, 2023 | 14.75 Mn |
| Dec 31, 2022 | 13.54 Mn |
| Sep 30, 2022 | 13.72 Mn |
| Jun 30, 2022 | 13.10 Mn |
| Mar 31, 2022 | 13.10 Mn |
| Dec 31, 2021 | 12.58 Mn |
| Sep 30, 2021 | 12.72 Mn |
API Access
Ocular Therapeutix Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=OCUL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "OCUL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=OCUL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();